BackgroundCell-based therapy is a treatment method in tendon injuries. Bone morphogenic protein 12 (BMP-12) possesses tenogenic activity and was proposed as a differentiating factor for stem cells directed to transplantation. However, BMPs belong to pleiotropic TGF-β superfamily and have diverse effect on cells. Therefore, the aim of this study was to determine if BMP-12 induces tenogenic differentiation of human adipose stem cells (hASCs) and how it affects other features of this population.ResultsHuman ASCs from 6 healthy donors were treated or not with BMP-12 (50 or 100 ng/ml, 7 days) and tested for gene expression (COLL1, SCX, MKH, DCN, TNC, RUNX2), protein expression (COLL1, COLL3, MKH), proliferation, migration, secretory activity, immunomodulatory properties and susceptibility to oxidative stress. RT-PCR revealed up-regulation of SCX, MKH and RUNX2 genes in BMP-12 treated cells (2.05, 2.65 and 1.87 fold in comparison to control, respectively, p < 0.05) and Western Blot revealed significant increase of COLL1 and MHK expression after BMP-12 treatment. Addition of BMP-12 significantly enhanced secretion of VEGF, IL-6, MMP-1 and MPP-8 by hASCs while had no effect on TGF-β, IL-10, EGF and MMP-13. Moreover, BMP-12 presence in medium attenuated inhibitory effect of hASCs on allo-activated lymphocytes proliferation. At the same time BMP-12 displayed no influence on hASCs proliferation, migration and susceptibility to oxidative stress.ConclusionBMP-12 activates tenogenic pathway in hASCs but also affects secretory activity and impairs immunomodulatory potential of this population that can influence the clinical outcome after cell transplantation.Electronic supplementary materialThe online version of this article (doi:10.1186/s12860-017-0129-9) contains supplementary material, which is available to authorized users.

No abstract

No abstract

The efficacy of two methods of Langerhans islets immunoisolation was compared. For this purpose the function of islets encapsulated with alginate/polyethylenimine/protamine/heparin (APPH) or with alginate/poly-L-lisine/alginate (APA) membranes was assessed: in vitro according to their survival and response to glucose challenges, and in vivo according to their capability to provide sufficient insulin delivery to maintain normal fasting blood glucose following xenotransplantation to streptozotocin diabetic mice. In vitro insulin secretion and the response to glucose challenge of APPH and APA encapsulated islets were comparable to free islets. In vivo intraperitoneal concordant xenotransplantation of APA encapsulated rat islets reversed the diabetic state of streptozotocin diabetic mice for a longer period, than APPH islet grafts. This study clearly demonstrated the inadequacy of in vitro methods in the prediction of in vivo results of islets transplantation.

InTRoduCTIon The discovery of a cure for diabetes is a dream of many medical researchers. The transplantation of Langerhans islets is a potential treatment of choice for patients with type 1 diabetes as a source of endogenous insulin for the recipient. objECTIVEs The aim of the experiment was to transplant Langerhans islets without immunosuppression. To protect the grafts against transplant rejection, semipermeable membranes could be used. MATERIAL And METhods Langerhans islets were isolated from rats and pigs and immunoisolated by encapsulation in alginate-protamine-heparin (APH) or alginate-poly-L-lysine-alginate (APA) membranes. Islets were pooled in a controlled manner. Tests for cryopreservation and bio compatibility were also performed. REsuLTs The capsules coated with APH are more resistant than the capsules coated with APA. After transplantation of the islets immunoisolated with APA, euglycemia is maintained longer than after transplantation of the islets immunoisolated with APH. Microencapsulation protects the islets from destruction by the host. ConCLusIons It is feasible to treat experimental diabetes by transplantation of encapsulated Langerhans islets without immunosuppression.